Back to School: How biopharma can reboot drug development. Access exclusive analysis here
ACEL (Bloomfield, N.J.) reported Phase I/II findings in 32 evaluable patients, eight of whom
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury